iBio (IBIO) Leerink Global Healthcare Conference 2026 summary

Strategic vision and therapeutic focus

• Pivoted to cardiometabolic disease, targeting areas beyond GLP-1s in obesity treatment.

• Employs a portfolio approach with multiple mechanisms to de-risk development in a high-attrition field.

• Focuses on innovative antibody therapies, particularly targeting Activin E, and aims to address unmet needs in obesity and related diseases.

• Sees opportunities in combination therapies with GLP-1s and potential for weight maintenance indications.

• Considers expanding into related areas such as Type 2 diabetes, MASH, cardiovascular disease, and sleep apnea.

Pipeline progress and clinical milestones

• Plans to file Activin E IND by year-end, with first patient dosing in the first half of next year and possible interim data by year-end.

• Bispecific myostatin/activin A program is six months behind Activin E, targeting clinic entry in the second half of next year.

• Myostatin program recently filed in Australia, aiming for first patient dosing as early as Q3.

• Non-human primate data for Activin E antibody aligns with recent human data, supporting translational potential.

• Biomarker and inflammation data from ongoing studies will inform phase IIa design and patient selection.

Competitive differentiation and technology platform

• Antibody approach targets protein in blood, aiming for near-complete pathway inhibition and potentially superior efficacy over siRNA.

• Antibodies offer validated safety and scalable manufacturing advantages compared to siRNA.

• AI-enabled drug discovery platform integrates in silico and traditional methods, optimizing both antibody and antigen design.

• Mammalian display platform enables simultaneous optimization of developability, expression, and specificity.

• Only known company with an antibody against Activin E, engineered for high developability and safety.